The rapid increase in bacterial resistance to antibiotics is a global healthcare crisis. Non-antibiotic pharmaceuticals that have attained approval by the United States Food and Drug Administration have the potential to be repurposed as bacterial resistance-modifying agents and therefore could become valuable resources in our battle against antibiotic-resistant microbes. Amoxapine is a tetracyclic antidepressant used in the treatment of major depressive disorder. Here we demonstrate the ability of amoxapine to resensitize methicillin-resistant Staphylococcus aureus strain ATCC 43300 to oxacillin in both agar diffusion and broth microdilution assays. Amoxapine also reduced the bacterial cleavage of nitrocefin in a dose-dependent manner, suggesting that it may exert its adjuvant effects through reduction of beta-lactamase activity.

细菌对抗生素的耐药性迅速增加是全球医疗保健危机。已获得美国食品与药物管理局（FDA）批准的非抗生素药物有可能被重新用作细菌抗药性改良剂，因此有可能成为我们与抗生素抗药性微生物斗争中的宝贵资源。阿莫沙平是一种用于治疗重度抑郁症的四环抗抑郁药。在这里，我们证明了阿莫沙平重新敏感性耐甲氧西林金黄色葡萄球菌的能力在琼脂扩散法和肉汤微稀释法中，将ATCC 43300菌株转化为奥沙西林。阿莫沙平还以剂量依赖的方式减少了硝菌素的细菌裂解，表明其可能通过降低β-内酰胺酶活性发挥其佐剂作用。